title: [Intermediate-dose cytosine arabinoside therapy in refractory acute leukemia].
authors.affiliation: Third Dept. of Internal Medicine, Akita University School of Medicine.
authors.forename: A
authors.initials: A
authors.lastname: Ohshima
authors.forename: K
authors.initials: K
authors.lastname: Yoshida
authors.forename: S
authors.initials: S
authors.lastname: Miyazaki
authors.forename: Y
authors.initials: Y
authors.lastname: Fukushima
authors.forename: A B
authors.initials: AB
authors.lastname: Miura
authors.forename: K
authors.initials: K
authors.lastname: Endo
authors.forename: H
authors.initials: H
authors.lastname: Ando
authors.forename: H
authors.initials: H
authors.lastname: Sasaki
authors.forename: S
authors.initials: S
authors.lastname: Saito
authors.forename: I
authors.initials: I
authors.lastname: Sato
mesh_terms: D000208:Acute Disease; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014750:Vincristine; D004317:Doxorubicin; D001215:Asparaginase